EUVIMEDEUVIMED entdecken
Open Access

Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA

Joel Iff iD, Yi Zhong iD, Edward Tuttle, Deepshekhar Gupta, Xander Paul, Erik Henricson iD

Journal of Comparative Effectiveness Research · 2023

DOI: 10.57264/cer-2023-0086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2023. Verfasst von Joel Iff und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sarepta Therapeutics, Inc., Cambridge, MA 02142, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate treatment effects of eteplirsen among patients with Duchenne muscular dystrophy.

Methods

Using real-world claims and electronic medical record data, this retrospective comparative analysis assessed eteplirsen-treated and control cohorts matched by age, disease progression state, and pre-index period healthcare resource utilization. Poisson regression was used to evaluate eteplirsen effects on healthcare resource utilization outcomes.

Results

Eteplirsen was associated with statistically significant reductions in rates of hospital encounters (31%), emergency room visits (31%), need for pulmonary management (33%), cardiac management (21%), tracheostomy (86%), and assisted ventilation (39%) versus the control group. Other assessed outcomes favored eteplirsen numerically but did not all reach statistical significance.

Conclusion

Eteplirsen-treated patients had reduced rates of multiple healthcare resource utilization measures versus matched controls.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneHumansUnited StatesRetrospective StudiesDisease ProgressionElectronic Health RecordsMorpholinos

Stichwörter der Autor:innen

Duchenne muscular dystrophydisease burdeneteplirsenreal-worldtreatment effects

Substanzen

eteplirsenMorpholinos

Autor:innen und Institutionen

  • Sarepta Therapeutics, Inc., Cambridge, MA 02142, USA.
  • Analysis Group, Inc., Menlo Park, CA 94025, USA.
  • UC Davis Medical Center, Sacramento, CA 95817, USA.

ORCID-Profile: Joel Iff, Yi Zhong, Erik Henricson

Zitieren

APA

Iff, J., Zhong, Y., Tuttle, E., Gupta, D., Paul, X., & Erik Henricson (2023). Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0086

Vancouver

Iff J, Zhong Y, Tuttle E, Gupta D, Paul X, Erik Henricson. Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA. Journal of Comparative Effectiveness Research. 2023. doi:10.57264/cer-2023-0086

BibTeX
@article{Iff2023,
  author = {Iff, Joel and Zhong, Yi and Tuttle, Edward and Gupta, Deepshekhar and Paul, Xander and Erik Henricson},
  title = {Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2023},
  doi = {10.57264/cer-2023-0086}
}
Kostenlos starten →